Mindpath Health

Mindpath Health in San Jose, California offers Spravato (esketamine) for adults with treatment-resistant depression who have not found sufficient relief from psychiatry and therapy alone. Spravato is the only FDA-approved, self-administered nasal spray for treatment-resistant depression and is commonly prescribed with antidepressant medications and therapy.

Spravato is self-administered twice weekly under clinician supervision, with a two-hour in-office observation period after each dose. After the first four weeks, the clinician sets the appropriate ongoing treatment schedule.

National data shows about 50% of esketamine patients experience at least a 50% improvement in depressive symptoms. The San Jose office also provides TMS, psychiatry, medication management, and therapy, and is in-network with most major commercial insurance plans in California.